Plasma-Centric Drugmaker Grifols To Buy Geriatric Pharma Startup Alkahest
Blood plasma and diagnostics company Grifols SA (NASDAQ: GRFS) is set to completely acquire Alkahest Inc, a biopharmaceutical startup focussed on neurodegenerative and age-related diseases, for $146 million on a debt-free basis.
